Abstract
The coagulopathy associated with Coronavirus disease 2019 (COVID-19)
leads to a thrombotic burden. To date, solely interim thromboprophylaxis
guidance have been established, gaps in evidence are remaining,
especially for ambulatory COVID-19 patients. We report a case COVID-19
in a patient with Glanzmann thrombasthenia, a rare platelet disorder
associated with a high bleeding tendency. Our experience emphasizes the
difficulty to manage such a condition, given the balance between
thrombotic and bleeding tendencies, and the unavailability of
evidence-based guidelines. Moreover, we detail hereinafter how patient’s
bleeding disorder made COVID-19 diagnosis very difficult, thus
highlighting the limits in actual SARS-CoV-2 molecular assays.